Zhangzhou Pientzehuang Pharmaceutical Co Ltd banner

Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436

Watchlist Manager
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Logo
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Watchlist
Price: 143.55 CNY 3.04% Market Closed
Market Cap: ¥86.6B

P/E

35.8
Current
22%
Cheaper
vs 3-y average of 45.9

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
35.8
=
Market Cap
¥100.4B
/
Net Income
¥2.4B

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
35.8
=
Market Cap
¥100.4B
/
Net Income
¥2.4B

Valuation Scenarios

Zhangzhou Pientzehuang Pharmaceutical Co Ltd is trading below its 3-year average

If P/E returns to its 3-Year Average (45.9), the stock would be worth ¥184.05 (28% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-29%
Maximum Upside
+74%
Average Upside
14%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 35.8 ¥143.55
0%
3-Year Average 45.9 ¥184.05
+28%
5-Year Average 62.2 ¥249.27
+74%
Industry Average 25.5 ¥102.27
-29%
Country Average 29.6 ¥118.82
-17%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
¥100.4B
/
Oct 2025
¥2.4B
=
35.8
Current
¥100.4B
/
Dec 2025
¥2.8B
=
35.4
Forward
¥100.4B
/
Dec 2026
¥3.2B
=
31.7
Forward
¥100.4B
/
Dec 2027
¥3.7B
=
27.1
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Market Distribution

In line with most companies in China
Percentile
56th
Based on 5 557 companies
56th percentile
35.8
Low
0 — 17.1
Typical Range
17.1 — 57.7
High
57.7 —
Distribution Statistics
China
Min 0
30th Percentile 17.1
Median 29.6
70th Percentile 57.7
Max 43 569.3

Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Glance View

Market Cap
86.6B CNY
Industry
Pharmaceuticals

Zhangzhou Pientzehuang Pharmaceutical Co. Ltd., nestled in the heart of Fujian Province, China, is a firm steeped in history and tradition, yet thriving in today’s modern pharmaceutical landscape. The company is best known for its signature product, Pientzehuang Pills, a centuries-old traditional Chinese medicine believed to offer hepatoprotective and detoxifying properties. Rooted in ancient formulations, Pientzehuang Pills are celebrated for their efficacy in addressing liver ailments and enhancing overall vitality. This has secured their place as a staple in Chinese households, maintaining cultural resonance while appealing to a broader audience through the global rise in demand for alternative medicine. The firm operates with a delicate balance, integrating traditional Chinese medicine practices with increasingly sophisticated production technologies to ensure quality consistency and scalability. Zhangzhou Pientzehuang leverages its brand heritage and expertise in traditional herbal remedies to drive revenue. The company has adeptly positioned itself within both domestic and international markets, capitalizing on the growing interest in holistic health approaches. By focusing on research and development, the company continues to innovate, expanding its product line to include health supplements and preventive solutions that cater to modern health challenges. Its strategic distribution channels, including hospitals, pharmacies, and online platforms, enable broad market penetration, ensuring robust sales growth. This dual strategy of preserving the traditional while embracing the modern allows the company to keep its legacy relevant in a competitive pharmaceutical industry, thereby securing its stronghold in the market and ensuring sustained financial performance.

Intrinsic Value
87.85 CNY
Overvaluation 39%
Intrinsic Value
Price ¥143.55
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett